H40.842: Neovascular secondary angle closure glaucoma, left eye
H40.842, neovascular secondary angle closure glaucoma, left eye, is listed as a covered diagnosis in 3 Medicare billing and coding articles that apply to 15 HCPCS Level II codes, including C9257 (Injection, bevacizumab, 0.25 mg), J7999 (Compounded drug, not otherwise classified), Q5129 (Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg). The articles come from 3 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.
HCPCS Level II codes with H40.842 as a covered diagnosis
| Code | Description | Medicare coverage | DMEPOS fee 2026 (state range) | Articles listing it |
|---|---|---|---|---|
| C9257 | Injection, bevacizumab, 0.25 mg | Special coverage instructions apply | — | 2 |
| J7999 | Compounded drug, not otherwise classified | Special coverage instructions apply | — | 1 |
| Q5129 | Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | Carrier judgment | — | 1 |
| Q5126 | Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | Carrier judgment | — | 1 |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | Carrier judgment | — | 1 |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | Special coverage instructions apply | — | 1 |
| J9035 | Injection, bevacizumab, 10 mg | Carrier judgment | — | 1 |
| J3590 | Unclassified biologics | Carrier judgment | — | 1 |
| Q5160 | Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg | Carrier judgment | — | 1 |
| J9312 | Injection, rituximab, 10 mg | Special coverage instructions apply | — | 1 |
| Q5123 | Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Carrier judgment | — | 1 |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Carrier judgment | — | 1 |
| Q5115 | Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | Special coverage instructions apply | — | 1 |
| J9260 | Injection, methotrexate sodium, 50 mg | Special coverage instructions apply | — | 1 |
| J9215 | Injection, interferon, alfa-n3, (human leukocyte derived), 250,000 iu | Special coverage instructions apply | — | 1 |
Medicare policy articles listing H40.842
- A53008: Billing and Coding: Intraocular Bevacizumab (Noridian Healthcare Solutions, LLC (MAC - Part A, MAC - Part B); 2 Level II codes)
- A52370: Billing and Coding: Bevacizumab and biosimilars (Wellpoint Federal (MAC - Part A, MAC - Part B); 8 Level II codes)
- A55639: Billing and Coding: Chemotherapy Agents for Non-Oncologic Conditions (WPS Insurance Corporation (MAC - Part A, MAC - Part B); 6 Level II codes)
A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.
Other H40 diagnoses (Glaucoma)
- H40.841 — Neovascular secondary angle closure glaucoma, right eye
- H40.843 — Neovascular secondary angle closure glaucoma, bilateral
Frequently asked questions
Does Medicare cover H40.842 (Neovascular secondary angle closure glaucoma, left eye)?
Medicare covers items and services, not diagnoses. 3 Medicare billing and coding articles list H40.842 as a covered diagnosis for 15 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.
Which HCPCS codes can be billed with ICD-10 H40.842?
The Level II codes from the policies most specific to this diagnosis are C9257 (Injection, bevacizumab, 0.25 mg, 2 articles); J7999 (Compounded drug, not otherwise classified, 1 article); Q5129 (Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg, 1 article); Q5126 (Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg, 1 article); Q5118 (Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg, 1 article). Code choice depends on the item supplied; check each code's descriptor.
Which Medicare policy articles list H40.842?
A53008 (Billing and Coding: Intraocular Bevacizumab); A52370 (Billing and Coding: Bevacizumab and biosimilars); A55639 (Billing and Coding: Chemotherapy Agents for Non-Oncologic Conditions).
What is ICD-10-CM code H40.842?
H40.842 is the ICD-10-CM code for neovascular secondary angle closure glaucoma, left eye, in category H40 (Glaucoma), chapter 7: Diseases of the eye and adnexa.
Next steps
- Run a reimbursement report for a device billed under C9257
- Watch C9257 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for C9257
Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.
Chapter 7: Diseases of the eye and adnexa · All diagnoses · HCPCS lookup